Texas-based biotechnology company Hope Biosciences reported that the US Food and Drug Administration (FDA) has approved a phase 2 clinical trial to study the effectiveness of own adipose tissue stem cells for the treatment of COVID-19. These are the mesenchymal stem cells, which can also be isolated from the umbilical cord, placenta, umbilical cord blood. In Ukraine, the Institute of Cell Therapy has developed a treatment protocol for COVID-19 using multipotent mesenchymal placental stem cells.
The coronavirus SARS-CoV-2 has been shown to infect the pulmonary vessels, and a damaged microcirculatory tract must be restored to cure a patient with severe coronavirus pneumonia. Mesenchymal stem cells have the ability to repair damaged tissues, as well as a prominent anti-inflammatory and immunomodulatory effect.
To date, COVID-19 cell therapy is carried out in clinical trials in the United States, China, Colombia, France, and Jordan. Mesenchymal stem cells, natural killer cells, exosomes of mesenchymal stem cells are used. About 30 such clinical trials have been reported and recovery has been reported repeatedly, even in elderly patients with severe COVID-19.
In Ukraine, the Institute of Cell Therapy is ready to provide 300 doses of placental mesenchymal stem cells, lacking ACE-2 receptors. The absence of ACE-2 receptors is a very important feature of placental mesenchymal stem cells, making them inaccessible to SARS-CoV-2, as the coronavirus can only attack cells that contain a receptor for angiotensin-converting enzyme (ACE-2).